<DOC>
	<DOCNO>NCT02128828</DOCNO>
	<brief_summary>The study hypothesis cenicriviroc improve cognition HIV infect individual cognitive impairment . The investigator study effect cenicriviroc cognition 24 subject 24 week period .</brief_summary>
	<brief_title>Effect Cenicriviroc HIV Neurocognitive Impairment</brief_title>
	<detailed_description>HIV-associated neurocognitive disease ( HAND ) , particularly milder form , estimate occur great 30 % HIV infected individual era potent antiretroviral therapy . As even mild disease lead functional consequence decrease ability live independently , HAND substantial public health concern . HIV-induced immune activation/inflammation monocyte ( MO ) may primarily responsible development HAND . Cenicriviroc combine CCR5 CCR2 chemokine co-receptor antagonist . The investigator hypothesize dual CCR5 CCR2 blockade use CVC lead measurable reduction MO activation lead cognitive improvement decrease HIV infection MO interrupt traffic MO central nervous system . The investigator propose single arm , 24-week trial CVC 24 subject HIV-1 infection suppress ART ( plasma HIV RNA &lt; 50 copies/ml ) 1 year mild moderate cognitive impairment .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>4.2.1.1 Documentation HIV1 infection FDA approve test time prior study entry On ARV medication uninterrupted &gt; 1 year lead screening period Screening plasma HIV RNA &lt; 50 copies/ml within 3 month entry Willingness male females childbearing potential utilize 2 effective contraception method ( 2 separate form , one must effective barrier method ) , nonheterosexually active exclusive vasectomize partner screen throughout duration study treatment 30 day follow last dose study drug . Age 18 70 year Ability willingness provide write informed consent Mild moderate cognitive impairment global neuropsychological ( NP ) test ( NPZglobal ) score &lt; 0.5 neurocognitive abnormality ( &lt; 0.5 ) least one cognitive domain know typically affected HIV OR unimpaired On antiretroviral ( ARV ) therapy consist nucleoside reverse transcriptase inhibitor , atazanavir with/or without ritonavir , darunavir plus ritonavir , dolutegravir , raltegravir efavirenz . Receiving use CCR5 antagonist within 6 month study entry Plasma HIV RNA &gt; 100 copies/ml within 6 mo . screen HIV2 Chronic hepatitis B ( positive hepatitis B surface antigen ) Chronic hepatitis C ( positive hepatitis C antibody ) , except proof viral clearance normal liver function test Active chronic liver disease Active inadequately treat tuberculosis infection , inadequate treatment positive purify protein derivative test . Adequate treatment meet current recommendation Center Disease Control , NIH HIV Medicine Association Infectious Diseases Society America ( IDSA ) guideline Center Disease Control recommendations patient treat current recommendation coinfection HIV . Prior/current diagnosis intracellular pathogen ( Listeria monocytogenes , Toxoplasma gondii , Cryptococcus neoformans ) . Uncontrolled seizure Current past malignancy exclude basal cell cancer Kaposi 's sarcoma ( skin ) . Immunomodulator , HIV vaccine , vaccine , investigational therapy within 30 day entry . Requirement acute therapy AIDSdefining serious medical illness within 14 day entry . Other chronic illness include hematologic , pulmonary , autoimmune disease endocrinopathies , except stable control diabetes cardiovascular disease view investigator stable testosterone thyroid therapy . Known hypersensitivity CVC excipients Anticipated need prescription medication allow study . Unwilling stop eating grapefruit use St. John 's wort ) . Chronic use counter medication unless approve Study Investigator Hemoglobin &lt; 8.5 ; Absolute neutrophil count &lt; 1000 ; Platelet count &lt; 100,000 ; serum glutamate oxaloacetate pyruvate transaminase &gt; 2.5x upper limit normal ; Lipase &gt; 2.0 x upper limit normal Estimated creatinine clearance &lt; 30 mL/min ( Cockcroft Gault 1979 ) Bradycardia , sinus rhythm &lt; 50 beats/min ( bpm ) . Presence condition would interfere absorption , distribution , metabolism , excretion drug Current active illicit substance alcohol use abuse , judgment Investigator , interfere patient 's ability comply protocol requirement Pregnancy breastfeed History moderate ( ChildPugh class B ) severe ( ChildPugh C ) hepatic impairment Patients , , opinion Investigator , unable comply dose schedule protocol evaluation study may advisable For MRI substudy [ impair ] : Any factor precludes MRI scan include presence metal exposure metal work ( e.g . metal grinder/worker ) claustrophobia For MRI substudy [ impair ] : Any central nervous system pathology , judgment investigator , interfere ability ass study change magnetic resonance spectroscopy 4.2.2.28 For lumbar puncture substudy : Thrombocytopenia bleed disorder ( include ongoing anticoagulant therapy ) , suspect increase intracranial pressure spinal epidural abscess , factor would increase risk complication follow lumbar puncture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>HIV-1-Associated Cognitive Motor Complex</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>